US Approval For Peanut Allergy Therapy Palforzia
Restrictions Could Limit Uptake
Executive Summary
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.
You may also be interested in...
Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
Podcast: Key Takeaways From J.P. Morgan
Scrip journalists join Datamonitor Healthcare's Mike Ramirez to share their impressions from the 2020 J.P. Morgan conference in San Francisco. Talking points range from M&A to the drug pricing debate, via individual company strategies, the impending US election and more.
Brexit Finally Here But Uncertainty Not Over For Biopharma
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
Need a specific report? 1000+ reports available
Buy Reports